The nation of Zimbabwe has turned down a major US health deal valued at $367m (272 million pounds) over five years over the United States' demand for sensitive information.
The decision became public following a official document from December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "skewed".
An official representative has since explained that the United States was demanding access to genetic material for scientific study and commercial gain but refused to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further talks to secure a deal suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Wider Background
Zimbabwe's decision follows a comparable situation in Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral deals to boost openness and responsibility.
According to statements, 16 nations in Africa have to date signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data for a long time, with no corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our population should a new health crisis arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting structures previously set up via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We welcome ongoing discussions with our US partners on how future collaboration could be structured in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts expressed it understood the government's concerns, but suggested that talks must proceed considering much of the nation's Aids initiatives relied on international support.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group said.
This impasse emphasises the complex challenges between accepting crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.